potentially expanding the market for GLP-1 therapies. The company’s focus on developing treatments for related conditions, such as NASH (non-alcoholic steatohepatitis), could also open up new ...

Roche linked its oral GLP-1 candidate CT-996 to 6.1% weight loss ... biotech of 'ruse' to raid trade secrets and make off with NASH cache Like the big names in obesity, Ascletis is advancing ...

potentially expanding the market for GLP-1 therapies. The company’s focus on developing treatments for related conditions, such as NASH (non-alcoholic steatohepatitis), could also open up new revenue ...

Madrigal Pharmaceuticals' Rezdiffra had a strong launch with $103.3M in Q4 sales and solid liquidity. See why I have a positive outlook on MDGL stock.

NASH can progress to cirrhosis or liver failure ... biggest threat facing Madrigal - the potential for approval for GLP-1 agonist drugs to treat MASH. For example, in November, Danish Pharma ...

Shares of Viking Therapeutics VKTX gained more than 11% on Wednesday after the company announced that it had signed a broad ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has shown ... which is also known as non-alcoholic steatohepatitis (NASH). The results come from Part 1 of the ESSENCE trial, which involved ...

The GLP-1 agonist makes your body release more insulin ... (This condition used to be called nonalcoholic steatohepatitis (NASH)). MASH is a buildup of fat in the liver, along with liver swelling ...

Ton Annual Supply of VK2735 Active Pharmaceutical Ingredient. Secures Dedicated Fill/Finish Capacity for 100 Million Annua ...

Viking's clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic ... of biopsy-confirmed non-alcoholic steatohepatitis (NASH) ...